GlobeNewswire by notified

Avextra AG and SynQube GmbH announce a Strategic Partnership in Drug Development with Cannabinoids and other Psychotropic Substances

  • Avextra, the leading European vertically-integrated manufacturer and developer of cannabis-based medicines is expanding its pharmaceutical development capabilities.
  • Behind SynQube GmbH are the two pioneers of cannabis medicine and founders of THC Pharm GmbH, Christian Steup and Holger Rönitz, with more than 25 years of experience with cannabinoids and psychotropic substances.
  • Together, Avextra and SynQube share a wealth of experience and are ideally positioned to pursue joint drug development to significantly improved care of critically ill patients with effective, safe and regulator approved medicines.
  • SynQube will work with Avextra to develop an innovative and safe manufacturing process.

BENSHEIM, Germany, June 20, 2024 (GLOBE NEWSWIRE) -- The leading European manufacturer and developer of Cannabis-based medicines Avextra AG (“Avextra”), is proud to announce a strategic partnership in drug development with SynQube GmbH based in Offenbach, Germany. SynQube GmbH is led by the founders of THC Pharm Christian Steup and Holger Rönitz, both pioneers in cannabinoid therapy in Europe with over 25 years of experience in pharmaceutical development and manufacturing of cannabinoid and other psychotropic substances.

THC Pharm, which emerged from a German patient initiative, was the first company to manufacture and distribute the active ingredient dronabinol (tetrahydrocannabinol, THC) on the continent and was a dominant player until its acquisition as part of the C3 consortium by Canopy Growth in 2019. Under the leadership of SycQube’s Managing Director Marc Zeplichal and other former THC Pharm colleagues, the two companies have created a joint platform in Offenbach, Germany where the synthesis of decades of experience and expertise can flow into joint drug development.

Together, Avextra and SynQube share a unique wealth of Cannabinoid experience and are ideally positioned to now accelerate innovative and high-quality drug development to address the significant unmet patient need with effective, safe and regulatory approved medicines. The strategic partnership is also structured for the long term in such a way that it can be underpinned by a reciprocal equity investment in the future. Within this partnership, Avextra will support a multi-center clinical trial at five sites in the EU with a psilocybin-based compound as an industry partner from 2025.

"We are delighted to be working with true pioneers of cannabinoid therapy and that Christian Steup, Holger Rönitz and the whole SynQube team will be part of Avextra’s clinical journey. This strategic partnership with SynQube also underscores our ability to execute our two-pillar strategy across six European markets," commented Dr. Bernhard Babel, CEO of Avextra AG.

"We see the legalisation of cannabis as an opportunity to redouble our focus on the therapy forms which meet reimbursement requirements to best serve seriously ill patients," said Holger Rönitz, COO at SynQube. "In recent years the medical cannabis space became clouded with recreational and more commercially driven interests. This hampered pharmaceutical development and created barriers to reimbursement. The partnership with Avextra enables us to transform our know-how in cannabinoids and other psychotropic substances into pharmaceutical development."

Avextra’s Supervisory Board Chairman Dr. Arno Gerken, added, "The partnership with SynQube represents a huge step forward for Avextra towards the development and distribution of our pharmaceutical products not only because of the remarkable skills of the joint team, but also because of the compatibility of the two corporate cultures with their clear dedication to addressing unmet patient need."

About Avextra AG
Avextra is one of Europe’s leading vertically-integrated medical cannabis operators focused on the development and production of regulator-approved medicines. Founded in 2019 and based out of Germany, the company works in close collaboration with doctors and pharmacists to develop and produce precisely formulated cannabis-based medicines. Avextra controls the entire value chain – from cultivation in Portugal to EU-GMP certified extraction and manufacturing in Germany. Avextra operates across continental Europe through an expansive distribution network of multiple channels and strategically developed assets for these key markets.

Learn more at and stay up to date at LinkedIn:

Avextra Investor Relations:
For further information, please contact our Investor Relations Team:

Avextra Media Enquiries: 
For media enquiries or to set up an interview please contact:
Phone: +49 30 408174037

SynQube: Holger Rönitz, Chief Operating Officer
Phone: +49 151 16204979

Forward-Looking Statement:
This news release contains certain "forward-looking information" within the meaning of applicable securities law. A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking information in this release including, but not limited to, the risk that: synergies and expected collaboration from the event may not be fully realised or may take longer to realise than expected; consumer demand for cannabis products globally falls short of expectations; Avextra's subsidiaries and partners are able to obtain and maintain the necessary regulatory authorisations to conduct business; and general economic, financial market, legislative, regulatory, competitive and political conditions in which Avextra and its subsidiaries and partners operate will remain the same.

The forward-looking information in this release is based on information currently available and what management believes are reasonable assumptions. The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Iveco Group signs a 150 million euro term loan facility with Cassa Depositi e Prestiti to support investments in research, development and innovation11.6.2024 12:00:00 CEST | Press release

Turin, 11th June 2024. Iveco Group N.V. (EXM: IVG), a global automotive leader active in the Commercial & Specialty Vehicles, Powertrain and related Financial Services arenas, has successfully signed a term loan facility of 150 million euros with Cassa Depositi e Prestiti (CDP), for the creation of new projects in Italy dedicated to research, development and innovation. In detail, through the resources made available by CDP, Iveco Group will develop innovative technologies and architectures in the field of electric propulsion and further develop solutions for autonomous driving, digitalisation and vehicle connectivity aimed at increasing efficiency, safety, driving comfort and productivity. The financed investments, which will have a 5-year amortising profile, will be made by Iveco Group in Italy by the end of 2025. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a

DSV, 1115 - SHARE BUYBACK IN DSV A/S11.6.2024 11:22:17 CEST | Press release

Company Announcement No. 1115 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-25478,1001,023.01489,100,86026:3 June 20247,0001,050.597,354,13027:4 June 20245,0001,055.705,278,50028:6 June20243,0001,096.273,288,81029:7 June 20244,0001,106.174,424,68

Landsbankinn hf.: Offering of covered bonds11.6.2024 11:16:36 CEST | Press release

Landsbankinn will offer covered bonds for sale via auction held on Thursday 13 June at 15:00. An inflation-linked series, LBANK CBI 30, will be offered for sale. In connection with the auction, a covered bond exchange offering will take place, where holders of the inflation-linked series LBANK CBI 24 can sell the covered bonds in the series against covered bonds bought in the above-mentioned auction. The clean price of the bonds is predefined at 99,594. Expected settlement date is 20 June 2024. Covered bonds issued by Landsbankinn are rated A+ with stable outlook by S&P Global Ratings. Landsbankinn Capital Markets will manage the auction. For further information, please call +354 410 7330 or email

Relay42 unlocks customer intelligence with a new insights and reporting module, powered by Amazon QuickSight11.6.2024 11:00:00 CEST | Press release

AMSTERDAM, June 11, 2024 (GLOBE NEWSWIRE) -- Relay42, a leading European Customer Data Platform (CDP), is leveraging Amazon QuickSight to power its new real-time customer intelligence, reporting, and dashboard module. Harnessing the breadth and quality of customer data, the new Insights module empowers marketing teams to dive deep into customer behaviors and gain invaluable insights into the performance of their marketing programs across all online, offline, paid, and owned marketing channels. Preview of the Relay42 Insights module, in pre-beta version Key capabilities of the Relay42 Insights module include: Deep insights into customer behaviors: With the Relay42 Insights module, marketers can ask unlimited questions about their data and gain a deeper understanding of how to serve their customers more effectively. Simplicity with AI-powered querying: Marketers can use artificial intelligence to query their data using natural language search, reducing the reliance on data scientists. Us

Metasphere Labs Announces X Spaces Event on the Topic of Green Bitcoin Mining and Sound Money for Sustainability11.6.2024 10:30:00 CEST | Press release

VANCOUVER, British Columbia, June 11, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere Labs" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is thrilled to announce an engaging Twitter Spaces event on Green Bitcoin mining, energy markets, and sustainability on July 3, 2024 at 2 p.m. ET. Follow us on X at MetasphereLabs for updates and to join the event. What We'll Discuss Bitcoin Mining Basics: Understand the fundamentals of Bitcoin mining.Energy Market Dynamics: Explore how Bitcoin mining interacts with energy markets.Sustainable Innovations: Learn about our efforts to promote sustainability in Bitcoin mining.Sound Money: Discover how tamper-proof currency can enhance stability.Efficient Payment Rails: See how fast, neutral payment systems support humanitarian projects.Carbon Footprint: Compare Bitcoin's environmental impact with traditional banking. "We're excited to host this event and dive into the critical topics of Bitcoin

HiddenA line styled icon from Orion Icon Library.Eye